{
    "clinical_study": {
        "@rank": "55376", 
        "arm_group": [
            {
                "arm_group_label": "eCMIT and Fluoxetine", 
                "arm_group_type": "Experimental", 
                "description": "expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)"
            }, 
            {
                "arm_group_label": "eCIMT and placebo", 
                "arm_group_type": "Experimental", 
                "description": "expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo"
            }, 
            {
                "arm_group_label": "Usual care and fluoxetine", 
                "arm_group_type": "Experimental", 
                "description": "Ususal physical care combined with Fluoxetine (FLX)"
            }, 
            {
                "arm_group_label": "Usual care and placebo", 
                "arm_group_type": "Experimental", 
                "description": "Usual physical care combined with placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Stroke patients who have little or no voluntary movement in the hand on the more affected\n      side of their body more than one year after stroke have few treatment options. This project\n      proposes to test the efficacy of a form of Constraint-Induced Movement therapy designed for\n      patients with such severe impairment in conjunction with an agent, fluoxetine, which has\n      been shown in some studies to enhance brain neuroplasticity in response to training.\n      Constraint-Induced Movement therapy, which is abbreviated CIMT, is a form of physical\n      rehabilitation based on basic research in neuroscience and behavioral science. If the\n      project is successful, an efficacious, evidence-based therapy will become available to\n      stroke patients for what is now a largely untreated condition"
        }, 
        "brief_title": "RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Stroke With Affected Arm Motor Function", 
        "condition_browse": {
            "mesh_term": [
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Motor criteria determinations will be made with the subject sitting. The\n             more-affected forearm will be resting on a supporting surface (e.g., arm of a chair)\n             to allow for maximum wrist flexion with gravity.\n\n          -  The minimum motor criterion (MMC) for inclusion in Grade 5 (severe impairment) will\n             be ability to:\n\n               -  initiate extension against gravity at the wrist or at least one digit,\n\n               -  initiate extension and flexion at the elbow,\n\n               -  actively move the shoulder \u2265 30\u00b0 in flexion, abduction, or scaption\n\n          -  The MMC for inclusion in Grade 4 (moderately severe impairment) will be ability to\n             actively:\n\n               -  extend at least two fingers more than 0\u00b0 but less than < 10\u00b0,\n\n               -  extend or abduct thumb \u2265 10\u00b0\n\n               -  extend wrist \u2265 10\u00b0 from a fully flexed starting position,\n\n               -  extend elbow \u2265 20\u00b0 from a 90\u00b0 flexed starting position,\n\n               -  flex and abduct shoulder > 45\u00b0.\n\n          -  Stroke patients who can extend at least two fingers \u2265 10\u00b0 at the metacarpophalangeal\n             (MCP) joint and either the proximal or distal interphalangeal (PIP or DIP) joint will\n             be excluded.\n\n          -  Additional inclusion criteria are:\n\n               -  must score \u2264 4 on the Modified Ashworth Scale (23)116 for all more-affected arm\n                  joints\n\n               -  meet the following passive range of movement criteria:\n\n                    -  \u2265 90\u00b0 shoulder flexion,\n\n                    -  \u2265 90\u00b0 shoulder abduction,\n\n                    -  \u2265 45\u00b0 shoulder external rotation,\n\n                    -  \u2264 30\u00b0 short of normal elbow extension, forearm supination to at least\n                       neutral,\n\n                    -  forearm pronation 45\u00b0 or more from neutral,\n\n                    -  \u2264 35\u00b0 short of normal wrist extension,\n\n                    -  \u2264 35\u00b0 short of normal MCP extension on all the digits.\n\n        Exclusion Criteria:\n\n          -  Less than 1 year post-stroke.\n\n          -  Frailty or insufficient stamina to carry out the requirements of the therapy (based\n             on clinical judgment).\n\n          -  Ferrous metal in body or medical complications or psychological problems that would\n             prohibit receiving an MRI.\n\n          -  Positive pregnancy test for women of child-bearing age since 3T MRI is\n             contraindicated for pregnant women.\n\n          -  Other neurological or musculoskeletal conditions affecting UE function.\n\n          -  Medication will not be exclusionary except in the following cases: a. participation\n             in any experimental drug study, b. Botox injections to the more-affected UE < 3\n             months prior to enrollment, c. Baclofen or Dantrium taken orally at the time of\n             study, d. fluoxetine or other antidepressant with SSRI-like properties taken < 3\n             months prior to enrollment, e. any agents that would contraindicate concurrent\n             fluoxetine. If subjects are on other medications, the medications will be recorded\n             and the possible effect on treatment outcome will be analyzed separately.\n\n          -  Moderate or greater depressive symptoms as indicated by a score > 30/63 on the Beck\n             Depression Inventory (24,25).117, 118\n\n          -  Concurrent participation in any formal physical rehabilitation program or clinical\n             trial.\n\n          -  Excessive pain in any joint of the more-affected arm that could limit ability to\n             cooperate with the intervention (based on clinical judgment).\n\n          -  Serious cognitive deficits manifested by a Folstein Mini-Mental State Examination\n             (MMSE) score \u2264 24 (26).119\n\n          -  Inadequate ability to follow test instructions as indicated by a Token Test of the\n             Multilingual Aphasia Examination score \u2264 36 (27).120\n\n          -  Serious, uncontrolled medical problems as judged by the Medical Director (e.g.,\n             severe rheumatoid arthritis, serious joint deformity of arthritic origin, symptomatic\n             cancer or renal disease, any end-stage pulmonary or cardiovascular disease, senility\n             or a deteriorated condition due to age, uncontrolled epilepsy).\n\n          -  Motor problems that are not primarily unilateral.\n\n          -  Poor motivation to participate in the study (if a person is only marginally\n             interested, he/she is a bad risk as a subject).\n\n          -  Less than 40 years old.\n\n          -  Previous CIMT."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963832", 
            "org_study_id": "F130410007"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "eCMIT and Fluoxetine", 
                    "eCIMT and placebo", 
                    "Usual care and fluoxetine"
                ], 
                "intervention_name": "Fluoxetine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "eCIMT and placebo", 
                    "Usual care and placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "eCMIT and Fluoxetine", 
                "intervention_name": "eCMIT", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Usual care and fluoxetine", 
                    "Usual care and placebo"
                ], 
                "intervention_name": "Usual Care", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluoxetine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "stroke", 
            "Fluoxetine (FLX)", 
            "eCIMT", 
            "Central Nervous System"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "contact": {
                "email": "guswatte@uab.edu", 
                "last_name": "Gitendra Uswatte, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35233"
                }, 
                "name": "University of Alabama at Birmingham"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This is a structured interview. Patients and family caregivers, if available, are asked to rate how well and how much the stroke survivor has used his or her more-affected arm on 30 upper-extremity tasks outside of the treatment setting over a specified period. The test score is the mean of the item scores. The primary outcome will be change on this instrument from pre- to post-treatment.", 
            "measure": "Grade 4/5 Motor Activity Log (MAL) Arm Use Scale", 
            "safety_issue": "No", 
            "time_frame": "baseline to 90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963832"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Alabama at Birmingham", 
            "investigator_full_name": "Gitendra Uswatte", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "See primary outcome.", 
                "measure": "Grade 4/5 MAL Arm Use scale", 
                "safety_issue": "No", 
                "time_frame": "baseline to 12 months after therapy"
            }, 
            {
                "description": "This is a laboratory motor performance test. Patients are asked to complete the items are rapidly as possible. Performance is timed and converted to a rate (repetitions/60 s). The test score is the mean of the item scores.", 
                "measure": "Grade 4/5 Wolf Motor Function Test Performance Rate score", 
                "safety_issue": "No", 
                "time_frame": "baseline to 90 days"
            }
        ], 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}